The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645

Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer

Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,520

In situ immune response and mechanisms of cell damage in central nervous system of fatal cases microcephaly by Zika virus

Azevedo, R. S. S., de Sousa, J. R., Araujo, M. T. F., Martins Filho, A. J., de Alcantara, B. N., Araujo, F. M. C., Queiroz, M. G. L., Cruz, A. C. R., Vasconcelos, B. H. B., Chiang, J. O., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-17765-5 · Cited by 3,478

Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer

Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967

Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study

Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836

Augmenting the Antitumor Efficacy of Natural Killer Cells via SynNotch Receptor Engineering for Targeted IL-12 Secretion

Ahmadnia, A., Mohammadi, S., Yamchi, A., Kalani, M. R., Farazmandfar, T., Khosravi, A., & Memarian, A. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040183 · Cited by 14

Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment

Zhang, J., Guo, Y., Fang, H., Guo, X., & Zhao, L. (2023) · Autoimmunity · doi:10.1080/08916934.2023.2259126 · Cited by 14

PARP in colorectal cancer: Molecular mechanisms, immunity, clinical trials, and drug combinations

Wu, F., Wei, H., Deng, H.-Y., Xiao, G.-H., & Zhang, Y. (2022) · Neoplasma · doi:10.4149/neo_2022_220724n745 · Cited by 13

Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancer

Kang, N., Xue, H., Lin, Y., Dong, X., Classen, A., Wu, R., Jin, Y., Lin, D., Volik, S. V., Ong, C. J., et al. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00644-9 · Cited by 15

SLC7A5 correlated with malignancies and immunotherapy response in bladder cancer

Zhang, C., Wang, Y., Guo, X., Wang, Z., Xiao, J., & Liu, Z. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03365-7 · Cited by 13

A tumor targeted nano micelle carrying astragaloside IV for combination treatment of bladder cancer

Kong, C., Sun, J.-R., Hu, X., Li, G., & Wu, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-66010-3 · Cited by 13

Phytochemical synergies in BK002: advanced molecular docking insights for targeted prostate cancer therapy

Park, M. N., Choi, J., Fahim, M. M. H., Asevedo, E. A., Nurkolis, F., Ribeiro, R. I. M. D. A., Kang, H. N., Kang, S., Syahputra, R. A., & Kim, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1504618 · Cited by 14

Development and Verification of an Autophagy-Related lncRNA Signature to Predict Clinical Outcomes and Therapeutic Responses in Ovarian Cancer

Li, Y., Wang, J., Wang, F., Gao, C., Cao, Y., & Wang, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.715250 · Cited by 13

Organ Specific Copy Number Variations in Visceral Metastases of Human Melanoma

Papp, O., Doma, V., Gil, J., Marko‐Varga, G., Kárpáti, S., Tı́már, J., & Vízkeleti, L. (2021) · Cancers · doi:10.3390/cancers13235984 · Cited by 13

An integrative approach of digital image analysis and transcriptome profiling to explore potential predictive biomarkers for TGFβ blockade therapy

Pomponio, R. J., Tang, Q., Mei, A., Caron, A., Coulibaly, B., Theilhaber, J., Rogers-Grazado, M., Sanicola-Nadel, M., Naimi, S., Olfati-Saber, R., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.013 · Cited by 13

Microphysiological systems as models for immunologically ‘cold’ tumors

Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 14

Autophagy inhibition improves the efficacy of anlotinib and PD-1 inhibitors in the treatment of NSCLC

Tang, H. J., You, T., Ge, H., Bai, C., Wang, Y., Sun, Z., Han, Q., & Zhao, R. C. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010812 · Cited by 12

Nucleic acid vaccines‐based therapy for triple‐negative breast cancer: A new paradigm in tumor immunotherapy arena

Saleh, R. O., Ibrahim, F. M., Pallathadka, H., Kaur, I., Ahmad, I. S., Ali, S. H. J., Redhee, A. H., Ghildiyal, P., Jawad, M. A., & Alsaadi, S. B. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3992 · Cited by 11

PD‐L1 regulates tumor proliferation and T‐cell function in NF2‐associated meningiomas

Wang, Y., Zhang, C., Yan, M., Ma, X., Song, L., Wang, B., Li, P., & Liu, P. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14784 · Cited by 12

Bacterial membrane vesicles combined with nanoparticles for bacterial vaccines and cancer immunotherapy

Xu, W. G., Maruyama, S., Sato, A., & Niidome, T. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.114125 · Cited by 12

PD-1+CD8+ T Cells Proximal to PD-L1+CD68+ Macrophages Are Associated with Poor Prognosis in Pancreatic Ductal Adenocarcinoma Patients

Yang, X., Wang, G., Song, Y., Zhuang, T., Li, Y., Xie, Y., Fei, X., Zhao, Y., Xu, D., & Hu, Y. (2023) · Cancers · doi:10.3390/cancers15051389 · Cited by 12

Co-targeting ferroptosis and immune evasion through small molecules in breast cancer

Zhou, J., Yang, W., Tang, H., Zou, Y., Zhou, Z., Peng, C., & Peng, F. (2025) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2025-0093 · Cited by 11

Magnetite nanoparticles: an emerging adjunctive tool for the improvement of cancer immunotherapy

Jungcharoen, P., Thivakorakot, K., Thientanukij, N., Kosachunhanun, N., Vichapattana, C., Panaampon, J., & Saengboonmee, C. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00220 · Cited by 13

Low-dose arsenic trioxide inhibits pancreatic stellate cell activation via LOXL3 expression to enhance immunotherapy in pancreatic cancer

Zhao, Y., Li, Y., Zou, J., Guo, T., Zhong, Z., Li, Y., Chen, S., Li, J., Huang, K., Lian, G., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02880-8 · Cited by 10

Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter

Wang, G., Liu, Y., Liu, S., Lin, Y., & Hu, C. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012647 · Cited by 10

Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial

Wang, Q., Tong, F., Li, Q., Qi, L., Sun, Y., Zhu, Y., Ni, J., Liu, J., Kong, W., Liu, B., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03744-z · Cited by 9

Understanding the relationship between breast cancer, immune checkpoint inhibitors, and gut microbiota: a narrative review

Hrubesz, G., Leigh, J., & Ng, T. L. (2024) · Translational Breast Cancer Research · doi:10.21037/tbcr-24-14 · Cited by 10

Tumor-Infiltrating Lymphocytes in Localized Prostate Cancer: Do They Play an Important Role?

Vilaça, M., Pinto, J. C., Magalhães, H., Reis, F. C., & Mesquita, A. (2023) · Cureus · doi:10.7759/cureus.34007 · Cited by 9

Association of HLA-A*11:01, -A*24:02, and -B*18:01 with Prostate Cancer Risk: A Case-Control Study

Manca, M. A., Simula, E. R., Cossu, D., Solinas, T., Madonia, M., Cusano, R., & Sechi, L. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015398 · Cited by 9

The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer

Yan, Z., Zhong, Z., Shi, C., Feng, M., Feng, X., & Liu, T. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2355705 · Cited by 9

Emerging immunologic approaches as cancer anti-angiogenic therapies

Azimi, M., Manavi, M. S., Afshinpour, M., Khorram, R., Vafadar, R., Rezaei‐Tazangi, F., Arabzadeh, D., Arabzadeh, S., Ebrahimi, N., & Aref, A. R. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03667-2 · Cited by 10

eIF5B regulates the expression of PD-L1 in prostate cancer cells by interacting with Wig1

Li, Q., Xiao, M., Shi, Y., Hu, J., Bi, T., Wang, C., Yan, L., & Li, X. (2021) · BMC Cancer · doi:10.1186/s12885-021-08749-w · Cited by 11

Unveiling the key mechanisms of FOLR2+ macrophage-mediated antitumor immunity in breast cancer using integrated single-cell RNA sequencing and bulk RNA sequencing

Wu, S.-X., Jiang, B.-H., Li, Z.-M., Tang, Y., Luo, L.-Q., Feng, W., Jiang, Y.-L., Tan, Y.-R., & Li, Y.-H. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-01980-4 · Cited by 8

Photodynamic Therapy Using RGD-Functionalized Quantum Dots Elicit a Potent Immune Response in a Syngeneic Mouse Model of Pancreatic Cancer

Li, M., Zhang, Y., Sun, F. Z., Huai, M., Zhang, F., Pan, J., Qu, C.-Y., Shen, F., Li, Z.-H., & Xu, L. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s479123 · Cited by 9

Effect of concomitant antibiotics use on patient outcomes and adverse effects in patients treated with ICIs

Yu, J., Yin, Y., Yu, Y., Cheng, M., Zhang, S., Jiang, S., & Dong, M. (2022) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2022.2145966 · Cited by 8

The impact of PD-L1 as a biomarker of cancer responses to combo anti-PD-1/CTLA-4

Parvini, S., Majidpoor, J., & Mortezaee, K. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154583 · Cited by 8

Breast cancer immunotherapy: a comprehensive review

Keshavarz, S., Wall, J. R., Keshavarz, S., Vojoudi, E., & Jafari-Shakib, R. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01177-z · Cited by 8

Therapies targeting triple-negative breast cancer: a perspective on anti-FGFR

Chen, J., Wang, Q., Wu, H.-Y., Huang, X., & Cao, C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1415820 · Cited by 6

The hexosamine biosynthetic pathway drives tumor immune evasion via translational control of PD-L1 at the elongation level

Liu, B., Wu, Y., Xiang, A.-Y., Yu, Y., Song, S., Zhang, Y., Gu, J., Lu, H., Xu, P., Liu, F., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116249 · Cited by 7

Fumarate Hydratase Enhances the Therapeutic Effect of PD-1 Antibody in Colorectal Cancer by Regulating PCSK9

Qin, L., Shi, L., Wang, Y., Yu, H., Du, Z., Chen, M., Cai, Y., Cao, Y., Deng, S., Wang, J., et al. (2024) · Cancers · doi:10.3390/cancers16040713 · Cited by 7

Identification of neutrophil extracellular traps (NETs)-related molecular clusters in prostate cancer: Implications for predicting biochemical recurrence

Zheng, W., Lin, F., Qiu, Q.-R.-S., Wu, Y., Ke, Z., Chen, S., Li, X., Sun, X., Zheng, Q., Wei, Y., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113908 · Cited by 7

Enhancing curcumol delivery through PD-1 targeted nanocarriers: A novel therapeutic approach for prostate cancer

Zhang, H., Du, Y., Liu, X., Gao, R., Xu, X., Hou, X., Liu, Z., Xin, P., Wu, W., Liu, T., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156595 · Cited by 7

Carboplatin enhances lymphocyte-endothelial interactions to promote CD8+ T cell trafficking into the ovarian tumor microenvironment

Mark, J., Fisher, D. T., Kim, M., Emmons, T. R., Khan, A. N. M. N., Alqassim, E., Singel, K. L., Mistarz, A., Lugade, A. A., Zhan, H., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.11.001 · Cited by 7

Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

Wang, Z.-Q., Wu, Z., Wang, Z.-P., Bao, J., Wu, H., Xu, D.-Y., Li, H.-F., Xu, Y.-Y., Wu, R.-X., & Dai, X. (2024) · BMC Cancer · doi:10.1186/s12885-024-12039-6 · Cited by 7

The FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies

Prajapati, K., Yan, C., Yang, Q., Arbitman, S., Fitzgerald, D. P., Sharee, S., Shaik, J. S., Bosiacki, J., Myers, K. V., Paucarmayta, A., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj4698 · Cited by 6

Transcriptome analysis of ovarian cancer uncovers association between tumor-related inflammation/immunity and patient outcome

Wang, J., Zhu, W., Li, X., Wu, Y., Ma, W., Wang, Y., Zhao, W., Wei, F., & Wang, W. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1500251 · Cited by 6

A Phosphatidylinositol 3‐Kinase Gamma Inhibitor Enhances Anti‐Programmed Death‐1/Programmed Death Ligand‐1 Antitumor Effects by Remodeling the Tumor Immune Microenvironment of Ovarian Cancer

Jiang, C., Liu, R., & Li, Z. (2025) · MedComm · doi:10.1002/mco2.70223 · Cited by 6

Polymer/copper nanocomplex-induced lysosomal cell death promotes tumor lymphocyte infiltration and synergizes anti-PD-L1 immunotherapy for triple-negative breast cancer

Hu, X., Wang, M., Shi, S., Raja, M. R. K., Gupta, G., Chen, H., & Xu, P. (2023) · Biomaterials Science · doi:10.1039/d3bm00627a · Cited by 6

The pan-cancer multi-omics landscape of key genes of sialylation combined with RNA-sequencing validation

Wu, Z., Wang, Z., Wu, H., Zheng, N., Huang, D., Huang, Z., Han, H., Bao, J., Xu, H., Zhang, R., et al. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107556 · Cited by 6

MRE11A: a novel negative regulator of human DNA mismatch repair

Du, D., Yang, Y., Zhang, Y., Wang, G., Chen, L., Guan, X., Rasmussen, L. J., & Liu, D. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00547-z · Cited by 7

Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy

Waters, C. M. (2021) · Open Biology · doi:10.1098/rsob.210277 · Cited by 6

Ethanol Ablation Therapy Drives Immune-Mediated Antitumor Effects in Murine Breast Cancer Models

Nief, C. A., Swartz, A. M., Chelales, E. M., Sheu, L. Y., Crouch, B. T., Ramanujam, N., & Nair, S. K. (2022) · Cancers · doi:10.3390/cancers14194669 · Cited by 6

CMTM7 recognizes an immune-hot tumor microenvironment and predicts therapeutic response of immunotherapy in breast cancer well

Jiang, X., Qian, Z., Chen, Y., Zhou, T. Y., Zhao, C., & Yin, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1051269 · Cited by 6

Evolution by innovation as a driving force to improve TCR-T therapies

Schendel, D. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1216829 · Cited by 6

The role of B cell immunity in lung adenocarcinoma

Shu, L., Tao, T., Xiao, D., Liu, S., & Tao, Y. (2025) · Genes and Immunity · doi:10.1038/s41435-025-00331-9 · Cited by 5

Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review

Rosenfeld, R., Sganga, S., Badalamenti, M., Mortellaro, S., Scorsetti, M., Garrone, O., Iannantuono, G. M., Chandran, E. B. A., Ghidini, M., & Franzese, C. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06245-3 · Cited by 5

Mechanisms of Anti-PD Therapy Resistance in Digestive System Neoplasms

Wu, Y., Jiang, X., Yu, Z., Xing, Z., Ma, Y., & Qing, H. (2024) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/0115748928269276231120103256 · Cited by 5

EREG silencing inhibits tumorigenesis via inactivating ERK/p38 MAPK pathway in pancreatic ductal adenocarcinoma

Liu, F., Wu, W., Cao, W., Feng, L., Yuan, J., Ren, Z., Dai, N., Wang, X., Li, X., & Yue, S. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167336 · Cited by 5

Radiotherapy and Immunotherapy—A Future Partnership towards a New Standard

Mireștean, C. C., Iancu, R. I., & Iancu, D. T. (2023) · Applied Sciences · doi:10.3390/app13095643 · Cited by 6

Anti-PD-L1 checkpoint inhibitor combined with nanocarrier-mediated cisplatin codelivery system for effective treatment of pancreatic cancer

Jia, Z.-Y., Yan, X., Zhou, H., Wang, W., Li, C., & Zhang, B. (2024) · Molecular Immunology · doi:10.1016/j.molimm.2024.08.006 · Cited by 5

Role of TIM-3 in ovarian cancer: the forsaken cop or a new noble

Chang, X., & Miao, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1407403 · Cited by 4

AICAR-loaded and panitumumab conjugated nanoparticles downregulate the expression of PD-L1 and enhance antitumor responses against ovarian cancer through the AMPK/STAT3 axis

Baniya, M. K., Duwa, R., Shrestha, P., Chang, J., Chun, K., & Yook, S. (2024) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-024-00702-w · Cited by 4

Evaluation of prognostic significance of histopathological characteristics and tumor-infiltrating lymphocytes for pancreatic cancer survival

Çorbacı, K., Gürleyik, G., Gönültaş, A., Aker, F., Gül, M. O., & Tilki, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-79342-x · Cited by 4

Pre-injection of exosomes can significantly suppress ovarian cancer growth by activating the immune system in mice

Wang, Y., Zhang, C., Zeng, H., Wang, L., Wang, Z., & Han, Z. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03951-2 · Cited by 4

Effect of tumor CD276 expression on infiltrating immune cells and clinicopathological features of prostate cancer

Liu, J., Kadier, A., Guo, Y., Zhang, W., Chen, H., Zhang, Z., Guo, C., Zhang, Y., Bao, M., Geng, J., et al. (2023) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-023-00690-2 · Cited by 4

The progress on the relationship between gut microbiota and immune checkpoint blockade in tumors

Jiang, H., Ye, Y., Wang, M., Sun, X., Sun, T., Chen, Y., Li, P., Zhang, M., & Wang, T. (2023) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2023.2212526 · Cited by 5

Targeting the Golgi apparatus enhances PD-L1 blockade and synergizes with oxaliplatin to improve immunotherapy efficacy

Li, H., Cui, C., Sun, C., Chen, Z., Gao, D., Yuan, P., Tian, S., Zhong, Q., Xu, F., Liang, X., et al. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.111343 · Cited by 3

Immune-related gene-based model predicts the survival of colorectal carcinoma and reflected various biological statuses

Kang, Z., Chen, B., Ma, X., Yan, F., & Wang, Z. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1277933 · Cited by 3

Landscape of costimulatory molecule signature in breast cancer and its prognostic significance

Kang, C., Yun, F., Shi, L., Jia, Y., & Liu, X. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-6245 · Cited by 3

Inhibitory effect of adenosine on adaptive antitumor immunity and intervention strategies

Wang, L., Zhang, W., ZHANG, J., Zheng, M., Pan, X., Guo, H., & Ding, L. (2023) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2023-0263 · Cited by 3

The safety and efficacy of systemic delivery of a new liver-de-targeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model

Shin, S. C., Vickman, R. E., Filimon, B., Yang, Y., Hu, Z., Mangold, K. A., Prabhakar, B. S., Schreiber, H. W., & Xu, W. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00735-1 · Cited by 3

Programmable mRNA 3′UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer

Huang, F., Yuan, F., Li, K., Cui, Y., Li, L., Ye, W., Cui, Z., Yan, J., Chen, Q., Nicchitta, C. V., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01720-9 · Cited by 2

Kikuchi disease: A case report about Sintilimab-induced Kikuchi histiocytic necrotizing lymphadenitis and literature review

Ren, C., Wang, Y., Yang, X., Tuo, Y., Li, Y., & Gong, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30608 · Cited by 3

Engineered immunologic niche monitors checkpoint blockade response and probes mechanisms of resistance

Raghani, R. M., Urie, R. R., Ma, J. A., Escalona, G., Schrack, I. A., DiLillo, K. M., Kandagatla, P., Decker, J. T., Morris, A. H., Arnold, K. B., et al. (2024) · ImmunoMedicine · doi:10.1002/imed.1052 · Cited by 2

Construction and Evaluation of an M2 Macrophage-Related Prognostic Model for Colon Cancer

Ji, M., Chen, Y., Zhang, L., Ying, L., Huang, C., & Liu, L. (2023) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-023-04789-z · Cited by 2

FOLR2-Positive Macrophages Suppress Breast Cancer Invasion Through T Cell ActivationPreprint

Jiang, B., Wu, S., Tang, Y., Zeng, L., Luo, L., Ouyang, L., Feng, W., Jiang, Y., Tan, Y., Xie, L., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4667619 · Cited by 2

Identification of Molecular Subtypes and Prognostic Features of Breast Cancer Based on TGF-β Signaling-related Genes

Qu, J., Wang, M., Gao, Y.-H., & Zhang, H. (2025) · Cancer Informatics · doi:10.1177/11769351251316398 · Cited by 2

Clinically friendly smart hydrogel boosts cuproptosis and PD-L1 upregulation to enhance anti-tumor immunotherapy

Fu, B., Li, G., Yao, Y., Zhang, M., Zhong, Y., Wang, X., Chen, Y., Liang, W., Wang, Y., Lin, H., et al. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102268 · Cited by 1

Glycoliposomes target lymphatic dendritic cells in a size-dependent manner to activate natural killer T cells against breast tumors

Hong, T., Masuda, K., Nakashima, Y., Li, S., Chen, P., Hu, G., Igarashi, K., Kimura, A., Fujita, K., Umezu, T., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114274 · Cited by 1

PD ‐1 Inhibitor (Sintilimab) Combined With Chemotherapy as Neoadjuvant Therapy in Advanced Ovarian Cancer: A Case Report

Zhenyan, W., & Wang, Y. (2026) · Clinical Case Reports · doi:10.1002/ccr3.73598 · Cited by 1

The Trinity: Interplay among Cancer Cells, Fibroblasts, and Immune Cells in Pancreatic Cancer and Implication of CD8+ T Cell-Orientated Therapy

Hung, Y., Chen, L., & Hung, W. (2022) · Biomedicines · doi:10.3390/biomedicines10040926 · Cited by 1

New Approaches Targeting Immuno-oncology and Tumor Microenvironment

Zhu, D., & He, F. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_89 · Cited by 1

Cuproptosis Depicts Immunophenotype and Predicts Immunotherapy Response in Lung Adenocarcinoma

Zhou, W., Cheng, Y., Li, L., Zhang, H., Li, X., Chang, R., Xiao, X., Lu, L., Yi, B., Gao, Y., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030482 · Cited by 1

Editorial: Community series in novel insights into immunotherapy targeting tumor microenvironment in ovarian cancer: volume II

An, T., Wang, H.-T., Wei, X., & Liang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1338119 · Cited by 1

Pre-existing cancer cells and induced fibroblasts are key cells for early chemoresistance in ovarian cancerPreprint

Gu, L., He, S., Wu, L., Zeng, Y., Zhang, Y., Zheng, C., Wu, C., Xu, H., Zhang, X., Shen, H., et al. (2024) · medRxiv · doi:10.1101/2024.02.03.24302058 · Cited by 1

Targeting triple-negative breast cancer with β1-integrin binding aptamerPreprint

Pleiko, K., Haugas, M., Parfejevs, V., Panteļejevs, T., Parisini, E., Teesalu, T., & Riekstiņa, U. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.28.501822

Immune Checkpoint Inhibitor Combination Therapy for Stage IV Pancreatic Cancer in 1 Case and Literature Review

韩, 娜. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.12111485

Identification of molecular subtypes and prognostic features of breast cancer based on TGF-β signaling-related genesPreprint

Wang, M., Gao, Y.-H., Qu, J., & Zhang, W. (2023) · Research Square · doi:10.21203/rs.3.rs-3426584/v1

Strategies for Application of Extracellular Vesicles in Solid Cancer Therapy

Majidpoor, J., Fathi, F., & Mortezaee, K. (2023) · Scientific Journal of Kurdistan University of Medical Sciences · doi:10.61186/sjku.28.4.160

Integrative analysis based on the cell cycle-related genes identifies TPX2 as a novel prognostic biomarker associated with tumor immunity in breast cancer

Liu, X., Wang, W., Chen, B., & Wang, S. (2024) · Aging · doi:10.18632/aging.205752

PD-1 interactome in osteosarcoma: identification of a novel PD-1/AXL interaction conserved between humans and dogs

Dziubek, K., Faktor, J., Lokhande, K. B., Shrivastava, A., Papak, I., Chruściel, E., Pilch, M., Hupp, T., Marek-Trzonkowska, N. M., Singh, A., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01935-w

Challenges in immunotherapy for PDAC: Overcoming immune resistance and enhancing treatment strategies

Kumari, S., & Nagaraju, G. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24742-2.00004-6

Immunotherapy in the Treatment of Melanoma

Katsouda, A., Rallis, T., Gogakos, A. S., Theocharidis, V., Kanteres, T., Tzinevi, M., Passos, I. D., & Mironidou‐Tzouveleki, M. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1011805

Ovarian oncosomes

Parmar, N. B., Desai, M. K., Parekh, P. S., Patel, R. B., Shah, D. D., Chorawala, M. R., Shah, P. A., & Bhupendra, G. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33536-5.00012-2

Additional file 2 of Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data

Deng, H., Wang, L., Wang, N., Zhang, K., Zhao, Y., Qiu, P., Qi, X., Zhang, D., Xu, F., & Liu, J. (2023) · Figshare · doi:10.6084/m9.figshare.22607462

Additional file 8 of SLC7A5 correlated with malignancies and immunotherapy response in bladder cancer

Zhang, C., Wang, Y., Guo, X., Wang, Z., Xiao, J., & Liu, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26725313

Additional file 4 of SLC7A5 correlated with malignancies and immunotherapy response in bladder cancer

Zhang, C., Wang, Y., Guo, X., Wang, Z., Xiao, J., & Liu, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26725301

Additional file 26 of SLC7A5 correlated with malignancies and immunotherapy response in bladder cancer

Zhang, C., Wang, Y., Guo, X., Wang, Z., Xiao, J., & Liu, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26725367

Additional file 14 of SLC7A5 correlated with malignancies and immunotherapy response in bladder cancer

Zhang, C., Wang, Y., Guo, X., Wang, Z., Xiao, J., & Liu, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26725331

Additional file 3 of Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data

Deng, H., Wang, L., Wang, N., Zhang, K., Zhao, Y., Qiu, P., Qi, X., Zhang, D., Xu, F., & Liu, J. (2023) · Figshare · doi:10.6084/m9.figshare.22607465

Additional file 2 of SLC7A5 correlated with malignancies and immunotherapy response in bladder cancer

Zhang, C., Wang, Y., Guo, X., Wang, Z., Xiao, J., & Liu, Z. (2024) · Figshare · doi:10.6084/m9.figshare.25902413

Additional file 1 of MRE11A: a novel negative regulator of human DNA mismatch repair

Du, D., Yang, Y., Zhang, Y., Wang, G., Chen, L., Guan, X., Rasmussen, L. J., & Liu, D. (2024) · Figshare · doi:10.6084/m9.figshare.26693218

Additional file 1 of Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data

Deng, H., Wang, L., Wang, N., Zhang, K., Zhao, Y., Qiu, P., Qi, X., Zhang, D., Xu, F., & Liu, J. (2023) · Figshare · doi:10.6084/m9.figshare.22607459

Additional file 11 of SLC7A5 correlated with malignancies and immunotherapy response in bladder cancer

Zhang, C., Wang, Y., Guo, X., Wang, Z., Xiao, J., & Liu, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26725322

Additional file 22 of SLC7A5 correlated with malignancies and immunotherapy response in bladder cancer

Zhang, C., Wang, Y., Guo, X., Wang, Z., Xiao, J., & Liu, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26725355

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients

Kumar, S., Chatterjee, M., Ghosh, P., Ganguly, K. K., Basu, M., & Ghosh, M. K. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.024 · Cited by 135

Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression

Asano, Y., Kashiwagi, S., Goto, W., Takada, K., Takahashi, K., Morisaki, T., Fujita, H., Takashima, T., Tomita, S., Ohsawa, M., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1458-y · Cited by 46

PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment—A Retrospective Study of PD-L1 Expression in Relation to Different Clinicopathological Parameters

Stanowska, O., Kuczkiewicz‐Siemion, O., Dębowska, M., Olszewski, W. P., Jagiełło-Gruszfeld, A., Tysarowski, A., & Prochorec‐Sobieszek, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195524 · Cited by 22

Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer

Chen, X., Feng, L., Huang, Y., Wu, Y., & Xie, N. (2022) · Cancers · doi:10.3390/cancers15010104 · Cited by 84

PD-1/PD-L1 axis importance and tumor microenvironment immune cells

Lotfinejad, P., Kazemi, T., Mokhtarzadeh, A., Shanehbandi, D., Jadidi‐Niaragh, F., Safaei, S., Asadi, M., & Baradaran, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118297 · Cited by 52